Because a high glycolytic consumption by tumor cells can dampen T-cell activation through NFAT1 down-regulation, interventions that have been shown to up-regulate NFAT1 in T-cells, including CDK4/6 inhibitors, such as amebaciclib or palbociclib, would also merit consideration. Here, NFATC2 is linked to neoplasm.